Effects of environmental steroid mixtures are regulated by individual steroid receptor signaling.
Abstract
Fish are exposed to steroids of different classes in contaminated waters, but their effects are not sufficiently understood. Here we employed an anti-sense technique using morpholino oligonucleotides to knockdown the glucocorticoid receptors (GRs, GRα and GRβ) and androgen receptor (AR) to investigate their role in physiological and transcriptional responses. To this end, zebrafish embryos were exposed to clobetasol propionate (CLO), androstenedione (A4) and mixtures containing different classes of steroids. CLO caused a decrease of spontaneous muscle contraction and increase of heart rate, as w...
Source: Aquatic Toxicology - July 2, 2020 Category: Toxicology Authors: Schmid S, Willi RA, Fent K Tags: Aquat Toxicol Source Type: research
A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal OGTT
Menopause is often associated with a central accumulation of body fat [1]. This may provoke insulin resistance, leading to hyperinsulinemia [2]. An increased insulin level is a risk factor for diabetes [3,4] and cardiovascular disease [5]. Moreover, the Women ’s Health Initiative (WHI) trial revealed that hyperinsulinemia is an independent risk factor for postmenopausal breast cancer [6]. As obese postmenopausal women have higher levels of estrogen, it is believed that estrogens are linked to increased breast cancer risk. (Source: Maturitas)
Source: Maturitas - April 28, 2020 Category: Primary Care Authors: H Depypere, A Dierickx, Velde F Van de, F Stanczyk, L Ottoy, J Delanghe, B Lapauw Source Type: research
Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study
To investigate the effectiveness and safety of 3 mg drospirenone and 20 μg ethinyl estradiol tablet (3 mg DRSP/20 μg EE) in the treatment of polycystic ovary syndrome (PCOS). (Source: BMC Women's Health)
Source: BMC Women's Health - February 27, 2020 Category: OBGYN Authors: Li Li, Ruiqin Zhang, Jing Zeng, Hu Ke, Xiuhong Peng, Liying Huang, Hongmei Zhang, Zhijing Chen, Tian Tian Li, Qiuxiao Tan, Ying Yang, Xiaofang Li and Xin Li Tags: Research article Source Type: research
Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study
ConclusionThe 24/4 YAZ regimen showed good safety profile, contraceptive reliability, good cycle control along with subgroup of patients. Improvements in dysmenorrhea and acne were also observed. No events of venous thromboembolism/arterial thromboembolism were reported.Trial RegistrationClinicalTrials.gov identifier, NCT02710708; Center for Drug Evaluation (CDE), China Food and Drug Administration (CFDA) number: CTR20160203. (Source: Advances in Therapy)
Source: Advances in Therapy - January 15, 2020 Category: Drugs & Pharmacology Source Type: research
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
Date: February 10, 2020
Issue #:
1591Summary:
The FDA has approved a progestin-only oral
contraceptive ( " minipill " ) containing drospirenone
(Slynd– Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available...
Source: The Medical Letter - January 2, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Pregnancy after mumps: a case report
ConclusionLow-dose contraceptive treatment containing progesterone, followed by Drospil, which includes both estradiol and progesterone, had a synergistic effect that led to the growth of the patient ’s uterus. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - December 21, 2019 Category: General Medicine Source Type: research
Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females
To determine the pharmacokinetics (PK) of drospirenone (DRSP), alone versus in combination with ethinyl estradiol (EE), after single and repeated administration.Study designWe conducted a single-centre, open-label, crossover, 2-treatment, 2-period, 2-sequence study in which non-micronized DRSP 4 mg or a combination of DRSP 3 mg and EE 0.02 mg were administered to healthy female subjects on day 1 to obtain a single-dose kinetic profile, and from day 4 to day 15 to obtain a repeated-dose kinetic profile. (Source: Contraception)
Source: Contraception - November 19, 2019 Category: OBGYN Authors: W.H. Richter, R. Koytchev, V. Kirkov, G. Merki, E. Colli, P.-A. Regidor Tags: Original Research Article Source Type: research
Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)
ConclusionsFurther research, however, is needed not only to define optimal duration, and to clarify the effects of treatment on long-term metabolic outcomes, but also to explore different treatment options and possible combined therapies. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - October 24, 2019 Category: Endocrinology Source Type: research
Bone health in estrogen-free contraception
This article reviews the effect of estrogens and progestogens on bone and presents new data of the currently approved drospirenone-only pill. The use of progestin-only contraceptives leading to an estradiol level between 30 and 50 pg/ml does not seem to lead to an acc elerate bone loss. (Source: Osteoporosis International)
Source: Osteoporosis International - August 23, 2019 Category: Orthopaedics Source Type: research
A high resolution LC–MS targeted method for the concomitant analysis of 11 contraceptive progestins and 4 steroids
Publication date: 25 October 2019Source: Journal of Pharmaceutical and Biomedical Analysis, Volume 175Author(s): Csaba Ferenc Laszlo, Jonathan Paz Montoya, Marie Shamseddin, Fabio De Martino, Alexandre Beguin, Rene Nellen, Stephen James Bruce, Marc Moniatte, Hugues Henry, Cathrin BriskenAbstractIn the context of hormonal contraception and hormone replacement therapy (HRT), many women are exposed to exogenous hormones. Current use of hormonal contraception with combined ethinyl estradiol and different progestins bestows a breast cancer relative risk (RR) of 1.2- while combined HRT has a RR of 2. Although these exposures pre...
Source: Journal of Pharmaceutical and Biomedical Analysis - August 5, 2019 Category: Drugs & Pharmacology Source Type: research
Drospirenone-containing contraceptive exerts positive effects on cardiac uric acid and PAI-1 but not GSK-3: Improved safety profiles in contraception?
Publication date: Available online 6 June 2019Source: PathophysiologyAuthor(s): Oluwaseun A. Adeyanju, Olaniyi A. Soetan, Lawrence A. OlatunjiAbstractThe use of combined oral contraceptives (COC) have been associated with increased risk of adverse cardiovascular events and elevated cardiac and circulating plasminogen activator inhibitor-1 (PAI-1) and glycogen synthase kinase-3 (GSK-3) have been implicated in these events. Contraceptives containing drospirenone, a progestin with anti-androgenic actions may have a positive or neutral effect on cardiac PAI-1 and GSK-3 levels. Studies on the favorable effects of oral contracep...
Source: Pathophysiology - June 6, 2019 Category: Pathology Source Type: research
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Date: July 1, 2019
Issue #:
1575Summary:
The FDA has approvedBijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketingBijuva as " the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule " . (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Activella Alora Angeliq bazedoxifene Bijuva Bioidentical Hormones Climara Combi-Patch Divigel Drospirenone Duavee Elestrin Estrogens Evamist femhrt Femring Hot flashes Medroxyprogesterone Menest Menopause Premarin Source Type: research
Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells - a prospective randomized trial
Long-term menopausal hormone treatment (MHT) has been associated with an increased risk of breast cancer [1]. This knowledge has resulted in a dramatic decline in the use of MHT during the last fifteen years. Still there are many women who request MHT for the alleviation of postmenopausal symptoms. Several factors have been identified to influence the risk of breast cancer, including breast tissue density as shown either by mammography or histology [2]. (Source: Maturitas)
Source: Maturitas - April 3, 2019 Category: Primary Care Authors: Angelica Lind én Hirschberg, Edneia Tani, Kerstin Brismar, Eva Lundström Source Type: research
combined oral contraceptive IN FEMALE MICE CAUSES HYPERINSULINEMIA DUE TO β-cell HYPERSECRETION AND REDUCTION IN INSULIN CLEARANCE
Publication date: Available online 25 March 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Cremilda Amaral Roso de Oliveira, Thiago dos Reis Araujo, Gésily de Souza Aguiar, Joel Alves da Silva Junior, Jean Franciesco Vettorazzi, Israelle Netto Freitas, Kênia Moreno de Oliveira, Antonio Carlos Boschero, Maria Lúcia Bonfleur, Júlia Rosauro Clarke, Helene Nara Henriques, Rosane Aparecida RibeiroAbstractOral contraception is the most commonly used interventional method in the world. However, several women employ the continuous use of these hormones to avoid pre- and menstruation discomforts...
Source: The Journal of Steroid Biochemistry and Molecular Biology - March 26, 2019 Category: Biochemistry Source Type: research
Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.
Abstract
In Germany one-third of the women in fertile age use combined oral contraceptives (COCs), which consist mostly of ethinylestradiol (EE) and a synthetic progestin. Older COCs with norethisterone or levonorgestrel have a lower risk for venous thromboembolism (VTE) than newer COCs with desogestrel, drospirenone, or gestodene. This is also true for nonoral combined hormonal contraceptives. The risk of newer COCs containing estradiol instead of EE is not clear due to missing data. Progestin-only hormonal contraception is not associated with a significant increase of the risk for VTE with the exception ...
Source: Hamostaseologie - January 22, 2019 Category: Hematology Authors: Rott H Tags: Hamostaseologie Source Type: research
